Hims & Hers Health continues to fire on all cylinders as a business. Click here to read why HIMS stock is a Buy.

Hims & Hers (NYSE: HIMS) has put investors on a roller coaster ride in 2025. *Stock prices used were the afternoon prices of ...

When investors choose to risk their capital in an individual company, they must be aware that the stock market isn’t the ...

Hims & Hers has delivered strong results and partnerships, but recent Cigna/Novo Nordisk news increases competitive risk and ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Hims & Hers Health, Inc (NYSE:HIMS) is facing heavy selling pressure Thursday morning as the U.S. Food and Drug Administration's (FDA) ban of compounded drugs with semaglutide takes effect.

Telemedicine company Hims & Hers has hired Farshad Shadloo to lead communications. As VP of communications, Shadloo reports ...

Hims & Hers stock price has surged and is nearing its all-time high as investors bet that its strong momentum will continue ...

Hims & Hers Health (HIMS) has received mixed ratings from Top Wall Street analysts, with Morgan Stanley (MS) maintaining a Hold rating while Citi (C) reiterates a Sell rating. The company’s strong app ...

Shares of Hims & Hers have gained 29% over the past week. The move higher has been driven by an impressive Q1 earnings report ...

Hims & Hers Health, Inc. (NYSE: HIMS) today announced eligible customers can access 6 months of prescription-only Wegovy® at ...

Online health and wellness company Hims & Hers raised $1 billion through convertible senior notes to grow its international ...